Skip to main content
Brii Biosciences Limited logo

Brii Biosciences Limited — Investor Relations & Filings

Ticker · 2137 LEI · 5493000GCQ47MM4EKK44 HKEX Manufacturing
Open in API
Filings indexed 278 across all filing types
Latest filing 2026-01-06 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2137

About Brii Biosciences Limited

http://www.briibio.com

Brii Biosciences Limited is a biotechnology company focused on developing therapies to address significant public health challenges. The company specializes in advancing first-in-class and/or different-in-class treatment options, primarily targeting infectious diseases and central nervous system diseases. Brii Bio concentrates its development efforts on therapeutic areas characterized by high unmet medical needs, social stigmas, and limited existing treatment options. Through scientific innovation and critical patient insights, the company is building an extensive pipeline designed to deliver differentiated therapeutic solutions.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by listed companies in Hong Kong to report monthly movements in securities, including share capital, share options, and other equity-related changes. Since it is a recurring regulatory disclosure required by the Exchange Listing Rules and does not fit into specific categories like 'Earnings Release' or 'Annual Report', it is classified as a Regulatory Filing (RNS).
2026-01-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for companies listed on the HKEX to report monthly movements in securities, including share capital, share options, and other equity-related changes. Since it details changes in share capital and issued shares, it falls under the category of share issues and capital changes.
2025-12-03 English
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE
Governance Information Classification · 1% confidence The document is titled 'Terms of Reference of the Nomination Committee' for Brii Biosciences Limited. It outlines the purpose, composition, authority, and responsibilities of the company's board-level committee. Such documents are foundational governance instruments that define how the board operates and are categorized under Governance Information (CGR) as they detail internal rules and board structure.
2025-11-16 English
VOLUNTARY ANNOUNCEMENT Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Brii Biosciences regarding clinical trial results (Phase 2 ENSURE study) presented at a medical conference (AASLD 2025). It provides scientific data, study methodology, and management commentary on the efficacy of their drug candidates. As it is a regulatory announcement regarding company business and clinical progress that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing.
2025-11-10 English
VOLUNTARY ANNOUNCEMENT Publication of Phase 2 ENSURE Study Results in Nature Medicine
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Brii Biosciences regarding the publication of clinical trial results (Phase 2 ENSURE study) in a medical journal. It provides details on the study design, methodology, and key clinical outcomes. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement (RPA) as it contains substantive scientific data and analysis. Since it is a general regulatory announcement regarding company operations and clinical progress that does not fall into specific categories like M&A or dividends, it is classified as a Regulatory Filing (RNS).
2025-11-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Exchange Listing Rules monthly return (Form FF301) detailing movements in authorized/registered share capital, issued shares, treasury shares, share options, and share awards for the month ended October 31, 2025. It is a regulatory disclosure of capital structure changes rather than an annual report, earnings release, or management presentation. This falls squarely under “Share Issue/Capital Change” (new shares issued, movements in share capital).
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.